A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BIIB074 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy
Phase of Trial: Phase II
Latest Information Update: 11 Aug 2017
At a glance
- Drugs Raxatrigine (Primary)
- Indications Neuropathic pain
- Focus Therapeutic Use
- Acronyms RELAY-1
- Sponsors Biogen; Convergence Pharmaceuticals
- 04 Apr 2017 Planned End Date changed from 1 Dec 2017 to 15 Dec 2017.
- 04 Apr 2017 Planned primary completion date changed from 1 Dec 2017 to 15 Dec 2017.
- 03 Nov 2016 Status changed from not yet recruiting to recruiting.